Compare TRVG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | IPHA |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | Germany | France |
| Employees | N/A | 163 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.0M | 189.5M |
| IPO Year | 2015 | N/A |
| Metric | TRVG | IPHA |
|---|---|---|
| Price | $4.39 | $1.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $3.95 | ★ $5.75 |
| AVG Volume (30 Days) | 64.4K | ★ 134.2K |
| Earning Date | 05-05-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.59 | $180.36 |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $1.18 |
| 52 Week High | $5.00 | $2.63 |
| Indicator | TRVG | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 69.31 | 52.02 |
| Support Level | $2.78 | $1.74 |
| Resistance Level | N/A | $1.80 |
| Average True Range (ATR) | 0.32 | 0.08 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 75.00 | 30.43 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.